GM-CSF增强免疫应答优化前列腺癌冷冻治疗的前瞻性随机临床试验
一项随机试点研究将20例前列腺癌患者分配至单纯冷冻治疗组或冷冻联合GM-CSF治疗组,用ELISpot和蛋白微阵列检测肿瘤相关抗原的T、B细胞应答。联合治疗组在4周和12周时癌症抗原相关抗体较基线的平均倍数变化均显著高于对照组(p<0.05),且前列腺抗原特异性T细胞应答增强更明显。提示冷冻治疗联合GM-CSF辅助免疫治疗可能产生治疗效应。
要点
- 冷冻联合GM-CSF组4周抗体较基线平均升高2.8%,对照组低于基线18%(p<0.05)。
- 12周联合组抗体升至基线以上25%,对照组仍低于基线9%(p<0.05)。
- 联合组ELISPOT读数在4周和12周均较高:PSA为527 vs 481,PAP为748 vs 562。
核心结论
- GM-CSF似乎广泛提升针对前列腺特异性和非特异性抗原的抗体。
- 前列腺抗原特异性T细胞应答比非前列腺特异性应答增强更明显,且优先出现在联合治疗组。
- 研究提示冷冻治疗联合辅助免疫治疗对前列腺癌可能有治疗效应。
研究设计与样本
- 前瞻性随机试点研究,共20例前列腺癌患者随机分配至单纯冷冻治疗组(对照组)或冷冻联合GM-CSF治疗组。
- 采用酶联免疫斑点(ELISpot)和蛋白微阵列(Sematrix)分别检测针对肿瘤相关抗原的T细胞和B细胞应答。
- 通过将治疗后ELISpot值相对于冷冻消融前平均应答进行归一化来计算应答倍数变化。
- 在4周和12周对所有抗原进行治疗组与对照组之间的Student t检验。
主要发现
- 冷冻治疗后4周,治疗组癌症抗原相关抗体较其平均基线值平均倍数变化高2.8%,而对照组平均低于基线18%(p<0.05)。
- 12周时,治疗组抗体应答升至基线以上25%,而对照组患者平均仍低于基线9%(p<0.05)。
- 治疗组在4周和12周时间点的平均ELISPOT读数较高:PSA为527 vs 481,PAP为748 vs 562。
临床怎么用
- 对于接受前列腺癌冷冻治疗的患者,可考虑联合GM-CSF以增强针对前列腺抗原的抗体和T细胞应答。
- 治疗期间可在4周和12周监测抗体倍数变化及ELISPOT读数以评估免疫应答。
局限性
- 本研究为试点研究,样本量仅20例,结论需更大规模试验验证。
- 原文未报告随访时长、临床终点(如无生化复发生存)及安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We explored the association of prostate cryotherapy and immunomodulation with granulocyte-macrophage colony-stimulating factor (GMCSF) in the generation of detectable tumor-specific T- and B-cell responses in men with prostate cancer. MATERIALS AND METHODS: A randomized pilot study of patients assigned to either cryotherapy alone (Control group) or in combination with GMCSF (Treatment group). The impact of therapy on the development of T- and B-cell responses against tumor-related antigens was studied using enzyme-linked immune absorbent spot (ELISpot) and protein microarray panels (Sematrix) assays, respectively. Fold changes in response to treatment were calculated by normalization of post-treatment ELISpot values against the mean pre-cryoablation response. Student t tests between treatment and control groups at 4 weeks and 12 weeks across all the antigens were performed. RESULTS: A total of 20 patients were randomized to either control or treatment arm. At 4 weeks after cryotherapy, the treatment group demonstrated an average fold change in cancer antigen-related antibodies of 2.8% above their mean baseline values, whereas controls averaged an 18% change below mean baseline (p < 0.05). At 12 weeks, antibody response in treatment group increased to 25% above baseline, while the average of control group patients remained 9% below baseline (p < 0.05). Patients in treatment group displayed, on average, higher ELISPOT readings for the 4- and 12-week times points (527 vs 481 for PSA and 748 vs 562 for PAP). CONCLUSIONS: GMCSF appeared to broadly elevate antibodies against prostate-specific and nonspecific antigens. Prostate antigen-specific T-cell responses were more enhanced over non-prostate-specific responses, preferentially in the treatment group. Our findings suggest a possible therapeutic effect of adjuvant immunotherapy in association with cryotherapy for the treatment of prostate cancer.
引用
- Barqawi AB, Rodrigues Pessoa R, Crawford ED, et al. Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial. Prostate Cancer Prostatic Dis. 2021. PMID: 33558662. doi:10.1038/s41391-021-00321-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。